Loading...
Loading...
Alnylam Pharmaceuticals, Inc.
ALNY, a leading RNAi therapeutics
company, announced today that the U.S. Food & Drug Administration (FDA) has
granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the
treatment of hemophilia B. Alnylam is developing ALN-AT3, a subcutaneously
administered RNAi therapeutic targeting antithrombin (AT), for the treatment
of hemophilia – including hemophilia A, hemophilia B, and hemophilia A or B
with “inhibitors” – and other Rare Bleeding Disorders (RBD).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in